Jul 8, 2014

U.S. regulators fast-track novel leukemia therapy

U.S. regulators on Monday put an experimental immunotherapy agent on the fast track to market approval, after 89 percent of leukemia patients in early trials saw their cancers disappear. The personalized immunotherapy known as CTL019 was developed by the University of Pennsylvania and was ...